Nilotinib Accord (Nilotinib)

Nilotinib is a targeted therapy that inhibits the BCR‑ABL tyrosine kinase pathway in certain blood cancers.

• Chronic myeloid leukemia (CML) in chronic phase: reduces leukemic cell proliferation and improves survival.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission by blocking BCR‑ABL signaling.

• Nilotinib selectively binds to the ATP‑binding site of the BCR‑ABL fusion protein, inhibiting its tyrosine kinase activity. This blockade prevents downstream signaling that drives uncontrolled proliferation of malignant hematopoietic cells, leading to cell cycle arrest and apoptosis of the leukemic clone.

Nilotinib may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Rash: mild skin irritation or redness.
• Nausea: feeling of sickness or urge to vomit.
• Diarrhea: loose or frequent stools.
• Elevated liver enzymes: increased ALT/AST levels detected in blood tests.

Serious or Rare Side Effects

• Cardiovascular events: including arterial occlusion, heart attack, or stroke.
• Severe pancreatitis: inflammation of the pancreas with abdominal pain.
• QT interval prolongation: heart rhythm disturbance that can lead to arrhythmia.

Before initiating therapy with Nilotinib, several safety considerations should be reviewed.

• Cardiac assessment: evaluate history of cardiovascular disease and monitor ECG.
• Liver function: check baseline hepatic enzymes and monitor periodically.
• Electrolytes: correct low potassium or magnesium to reduce QT risk.
• Drug interactions: avoid concomitant use of strong CYP3A4 inhibitors.
• Pregnancy and lactation: contraindicated; ensure effective contraception for women of childbearing potential.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Nilotinib can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nilotinib plasma levels, risking toxicity.
• Proton pump inhibitors (e.g., omeprazole) taken with nilotinib: can reduce absorption and efficacy.
• Antacids containing aluminum or magnesium: may decrease nilotinib bioavailability.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower nilotinib concentrations, reducing therapeutic effect.
• Concomitant QT‑prolonging drugs (e.g., amiodarone, fluoroquinolones): increase risk of cardiac arrhythmias; monitor ECG.